Compare VATE & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VATE | ONCY |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.3M | 106.1M |
| IPO Year | 1996 | 1999 |
| Metric | VATE | ONCY |
|---|---|---|
| Price | $4.54 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 16.3K | ★ 695.5K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,099,900,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.05 | $0.33 |
| 52 Week High | $13.79 | $1.51 |
| Indicator | VATE | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 32.98 | 46.86 |
| Support Level | $4.76 | $0.94 |
| Resistance Level | $5.28 | $1.01 |
| Average True Range (ATR) | 0.24 | 0.06 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 24.99 | 69.83 |
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.